Anti-Human IL 12/23 (Briakinumab) – Biotin
Anti-Human IL 12/23 (Briakinumab) – Biotin
Product No.: LT501
Product No.LT501 Clone ABT-874 Target IL-12/IL-23 p40 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names IL-12p40; Interleukin 12; Interleukin 23; IL12; IL23; IL-12; IL-23 Isotype Human IgG1λ Applications ELISA , FA , FC |
Antibody DetailsProduct DetailsReactive Species Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Active Immunogen This antibody was produced by phage display technology. Product Concentration 0.5 mg/ml Formulation This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This biotinylated antibody is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2893963 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Briakinumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. ELISA Additional Applications Reported In Literature ? FA Additional Reported Applications For Relevant Conjugates ? B N WB IF IP Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Briakinumab recognizes both human IL12 and IL23 via IL-12/23p40. This product is for research use only. Background Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23α to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.
Antigen Distribution IL-12 is produced by dendritic cells, macrophages, neutrophils, and human B-lymphoblastoid cells. IL-23 is mainly secreted by activated dendritic cells, macrophages or monocytes. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Research-grade Briakinumab biosimilars are used as calibration standards or reference controls in PK bridging ELISAs by serving as the analytical standard against which unknown serum sample concentrations are quantified, ensuring assay precision and comparability between biosimilar and reference products. In a PK bridging ELISA, the biosimilar (e.g., Briakinumab) is first thoroughly characterized for purity and concentration, often exceeding 95% purity and low endotoxin levels, as confirmed by multi-step affinity chromatography and rigorous quality control assessments. For the assay:
Benefits of Using Biosimilars as Calibration Standards:
Regulatory and Best Practice Notes:
In summary, research-grade Briakinumab biosimilars are critical reagents as calibration standards/reference controls in PK bridging ELISA, enabling the accurate, reproducible measurement of drug concentration in serum while supporting PK comparability between biosimilar and originator molecules. A standard Flow Cytometry protocol using a PE or APC-conjugated Briakinumab biosimilar to assess the expression or binding capacity of the IL-12/IL-23 p40 target involves the following key steps and considerations: 1. Sample Preparation
2. Antibody Staining
3. Washing
4. Data Acquisition
5. Controls and Validation
6. Data Analysis
Additional Notes
This protocol aligns with general best practices for antibody-based flow cytometry, specifically validated for PE and APC-conjugated Briakinumab biosimilar detection of the IL-12/IL-23 p40 target. Biopharma companies use a comprehensive range of analytical assays to confirm the structural and functional similarity of a proposed biosimilar to the originator drug. These include detailed structural analyses and functional (biological activity) assays. Key analytical assays typically performed:
How Leinco biosimilars are used in these studies:Leinco provides highly characterized biosimilar monoclonal antibodies and proteins that are used as reference standards, controls, or comparators in the analytical workflows. These biosimilars serve multiple key roles:
The use of Leinco biosimilars allows developers to conduct head-to-head comparisons (analytical similarity assessments) to verify that their candidate biosimilar matches the reference in both structure and function, as required by regulatory authorities. This is critical in both early- and late-stage characterization studies to ensure reliability, reproducibility, and regulatory compliance. Summary Table: Analytical Assays for Biosimilar Assessment
In summary, confirming biosimilarity requires a strategic, multifactorial analytical approach focused on both structural and functional attributes, with validated materials such as Leinco’s biosimilars providing a critical foundation for comparability and regulatory acceptance. References & Citations1. Vsn, M. et al. (2016) VALUE IN HEALTH 19 PSS5:A123 Technical ProtocolsCertificate of Analysis |
Formats Available
Prod No. | Description |
---|---|
LT500 | |
LT504 | |
LT502 | |
LT501 | |
LT511 | |
LT506 | |
LT505 | |
LT507 |
